In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Europe's New Spec Pharma Models

Executive Summary

Spec pharma has created significant value in the US, but not, so far, in Europe. Still, Europe's spec pharma hopefuls aren't giving up, and they're trying out variations on the theme--some starting with infrastructure, others with products.

Related Content

Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Almirall: Adapting Primary-Care-focused R&D to a Specialist World
Pharmion's Euro Bet Pays Off
Satraplatin's Stumble: Is Accelerated Approval Under Threat?
Co-Promotes: A Marketplace Reality, But Do They Make Sense?
Specialty Pharma: Tapping Japan
European Biotech Is Specialty Pharma
European Biotech Is Specialty Pharma
Ex-Shire Team Builds New Euro-Specialty Group
Ex-Shire Team Builds New Euro-Specialty Group


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts